Your browser doesn't support javascript.
loading
Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study.
Song, Yuqin; Gao, Quanli; Zhang, Huilai; Fan, Lei; Zhou, Jianfeng; Zou, Dehui; Li, Wei; Yang, Haiyan; Liu, Ting; Wang, Quanshun; Lv, Fangfang; Guo, Haiyi; Yang, Liudi; Elstrom, Rebecca; Huang, Jane; Novotny, William; Wei, Vivian; Zhu, Jun.
Afiliación
  • Song Y; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Beijing, China.
  • Gao Q; Department of Immunotherapy, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China.
  • Zhang H; Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
  • Fan L; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, China.
  • Zhou J; Department of Hematology, Tongji Hospital, Tongji Medical College, Wuhan, China.
  • Zou D; State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
  • Li W; Department of Hematology, Cancer Center, The First Hospital of Jilin University, Changchun, China.
  • Yang H; Department of Oncology, Zhejiang Cancer Hospital, Hangzhou, China.
  • Liu T; Department of Hematology, West China Hospital of Sichuan University, Chengdu, China.
  • Wang Q; Department of Hematology, Chinese PLA General Hospital, Beijing, China.
  • Lv F; Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
  • Guo H; BeiGene (Beijing) Co., Ltd., Beijing, China.
  • Yang L; BeiGene (Beijing) Co., Ltd., Beijing, China.
  • Elstrom R; BeiGene USA, Inc., San Mateo, CA, USA.
  • Huang J; BeiGene USA, Inc., San Mateo, CA, USA.
  • Novotny W; BeiGene USA, Inc., San Mateo, CA, USA.
  • Wei V; BeiGene (Beijing) Co., Ltd., Beijing, China.
  • Zhu J; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Beijing, China. zhu-jun2017@outlook.com.
Leukemia ; 34(2): 533-542, 2020 02.
Article en En | MEDLINE | ID: mdl-31520078
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedad de Hodgkin / Anticuerpos Monoclonales Humanizados / Receptor de Muerte Celular Programada 1 / Linfoma / Anticuerpos Monoclonales / Recurrencia Local de Neoplasia Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Leukemia Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2020 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedad de Hodgkin / Anticuerpos Monoclonales Humanizados / Receptor de Muerte Celular Programada 1 / Linfoma / Anticuerpos Monoclonales / Recurrencia Local de Neoplasia Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Leukemia Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2020 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido